RSV Vaccine Faces Cost and Insurance Challenges in U.S. Rollout

The rollout of two new immunizations, Pfizer's Abrysvo vaccine and Sanofi's Beyfortus monoclonal antibody, to protect infants from respiratory syncytial virus (RSV) is facing challenges in the United States. Providers are struggling with insurance coverage and the high cost of the immunizations, hindering their ability to offer protection to babies this winter. RSV can be dangerous for newborns, and complications from the virus are a leading cause of hospitalization among newborns. The new options, which cut the risk of severe disease or hospitalization by over 50%, aim to protect more newborns from RSV. Insurers are working to update their policies, but delays are expected as they navigate logistical issues.